Trending News

Woman tests blood glucose level
#Clinical trials #Diabetes #GLP-1 #Phesi #Type 2 diabetes

Increase in diabetes research fuelled by GLP-1s like Ozempic

Covid-19 is no longer in the top five most studied indications, replaced by type 2 diabetes, according to Phesi’s mid-year analysis of clinical trials. The analysis of 66,935 clinical trials reveals that the top five most studied diseases are now breast cancer, solid tumours, stroke, prostate… Read More

#News #Trending News

Colourised scanning electron micrograph of Marburg virus particles
#Clinical trial #Immunology / Virology & Vaccines #University of Oxford #Vaccine candidate

First-in-human vaccine trial for deadly Marburg virus

Scientists at the University of Oxford in the UK have launched a new clinical trial to test a vaccine to protect against “devastating” Marburg virus. This is the first-in-human trial of the ChAdOx1 Marburg vaccine, which has been developed and manufactured by researchers at the University… Read More

#News #Trending News

#Antibody drug conjugate (ADC) #Financing #Francis Crick Institute #Imperial College London #Myricx Bio #Start-ups

Myricx Bio announces £90m ($114m) Series A financing

UK biotech Myricx Bio has raised £90 ($114) million Series A financing to support the development of its N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) therapeutics. The round was co-led by new investors Novo Holdings and Abingworth, with additional support from British Patient Capital, Cancer Research Horizons and Eli Lilly, plus… Read More

#Business & Investment #News #Trending News

EMA concept
#Chronic obstructive pulmonary disease (COPD) #European Medicines Agency #Sanofi

Dupixent first targeted therapy for COPD approved in EU

The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils. The approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist… Read More

#News #Regulatory #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA approves second anti-amyloid beta antibody for Alzheimer’s

Eli Lilly’s anti-amyloid beta monoclonal antibody (mAb) Kisunla (donanemab) has become the second disease-modifying therapy for Alzheimer’s disease (AD) to reach the US market, following approval by the US Food and Drug Administration (FDA). It has been approved by the regulator for the treatment of patients with mild cognitive impairment… Read More

#News #Regulatory #Trending News

HIV cell
#Gilead Sciences #HIV #Phase III trial #Virology

Twice-yearly HIV injection demonstrates 100% efficacy

Interim analysis of the Phase III PURPOSE 1 trial indicates that Gilead Sciences twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrates 100% efficacy for the investigational use of HIV prevention in cisgender women. PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily… Read More

#News #Trending News

The Hospital for Sick Children (SickKids) in Toronto, Canada
#Gene therapy #Genetics / genomics #Neurodegenerative disorders #Rare disease

Gene therapy halts progression of rare genetic condition

The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50). SPG50 is an ultra-rare progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, progressive paralysis of all four limbs, and is typically fatal… Read More

#News #Trending News

Enterovirus
#Clinical trial #Monoclonal antibodies #National Institutes of Health (NIH) #Virology

Trial to test monoclonal antibody for virus of growing concern

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM). AFM has emerged in the United States… Read More

#News #Trending News

Man wearing a cap mask while sleeping
#American Diabetes Association #Diabetes #Eli Lilly #GLP-1 #Phase III trial #Sleep apnoea #Weight loss

Weight loss drug reduces sleep apnoea severity by 62%

Tirzepatide demonstrated a mean reduction of up to 62.8% on the apnoea-hypopnea index (AHI) compared to placebo in the SURMOUNT-OSA Phase III clinical trials. The drug was tested for the treatment of moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity, with and without positive airway… Read More

#News #Trending News

#American Diabetes Association #Diabetes #Events #GLP-1 #Obesity #Weight loss

New evidence on GLP-1 receptor agonists at ADA 2024

Further insights on glucagon-like peptide-1 (GLP-1) receptor agonists were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, 21-24 June. Obesity affects 41.9% of adults and 19.7% of children and adolescents in the US, and 90% of people with diabetes also live… Read More

#News #Trending News

#Cardiovascular disease #Diabetes #GLP-1 #UT Southwestern #Weight loss

Data confirms that semaglutide lowers blood pressure

US scientists have released new data supporting initial findings that diabetes and weight loss drug semaglutide (Wegovy/Ozempic) lowers cardiovascular risk regardless of blood sugar. A weekly dose of semaglutide 2.4mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight… Read More

#News #Trending News

Antibodies attacking virus
#Antibodies #Chiba University #Covid-19 #Immune system

Could auto-antibodies be linked to severe Covid-19?

Researchers have revealed that auto-antibodies block interferon signalling, contributing to severe Covid-19 by impairing the patient’s immune response. Scientists have found that some people who suffered from Covid-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signalling proteins. Factors such… Read More

#News #Trending News

Motor neuron disease awareness day
#Amyotrophic lateral sclerosis (ALS) #Motor neuron disease #Neurodegenerative disorders

Six advances in drug discovery for MND / ALS

Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). A new UK research partnership In June, UK charity LifeArc pledged £1.5 million to fund a… Read More

#News #Trending News

Gut microbiome
#Antibiotics #Antimicrobial resistance (AMR) #Gram-negative bacteria #Gut microbiome #University of Illinois

Antibiotic kills gram-negative bacteria, spares gut microbiome

Researchers have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections in mouse models of acute pneumonia and sepsis while sparing healthy microbes in the gut. The drug, called lolamicin, also warded off secondary infections with Clostridioides difficile, and was effective against more than… Read More

#News #Trending News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Close up of vaccine syringe
#Covid-19 #Covid-19 vaccine #Flu vaccine #Immunology / Virology & Vaccines #Influenza #Moderna

Combination vaccine better than separate flu and Covid-19 jabs

In clinical trials, Moderna’s combination vaccine elicited higher immune responses against influenza (flu) virus and SARS-CoV-2 than licensed flu and Covid-19 vaccines in adults 50 years and older. The Phase III trial investigated mRNA-1083, an investigational combination vaccine against influenza and Covid-19. mRNA-1083 comprises… Read More

#News #Trending News